Clinical Trials ProgressThe FDA has approved Adicet's IND for lupus nephritis, allowing the company to proceed with clinical trials.
Financial StabilityAdicet's strong cash position, with approximately $271 million in cash and equivalents, provides a solid financial foundation and a cash runway into the second half of 2026.
Regulatory MilestoneAdicet has received FDA Fast Track Designation for ADI-001 in the treatment of B-cell non-Hodgkin’s lymphoma, accelerating the development process.